Bayesian Capital Management’s Blueprint Medicines BPMC Stock Holding History

Bayesian Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-33,300	Closed	-$4.27M	–	556
2025 Q2	$4.27M	Buy	+33,300	New	+$3.46M	0.67%	25
2025 Q1	–	Sell	-18,579	Closed	-$1.62M	–	634
2024 Q4	$1.62M	Buy	+18,579	New	+$1.7M	0.2%	151
2024 Q3	–	Sell	-12,243	Closed	-$1.32M	–	706
2024 Q2	$1.32M	Buy	+12,243	New	+$1.23M	0.15%	176

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bayesian Capital Management's BPMC Position: Q3 2025 in Review

Bayesian Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 33,300 shares — an estimated $4.27M sold.

Bayesian Capital Management first reported a position in BPMC in Q2 2024 and held it in 3 quarters. The position peaked at $4.27M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Bayesian Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Bayesian Capital Management sold 33,300 Blueprint Medicines shares in Q3 2025, an estimated $4.27M.
Bayesian Capital Management first reported a position in Blueprint Medicines in Q2 2024 and held it in 3 quarters.
Bayesian Capital Management's Blueprint Medicines position peaked at $4.27M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Bayesian Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.